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Macromolecular structures provide an ideal starting point for the design and synthesis 
of small-molecule mimetics of surface epitopes that mediate protein-protein and 
protein-nucleic acid interactions. The resulting protein epitope mimetics (PEMs) 
provide a source of new biologically active molecules that are useful as biomolecular 
probes in chemical biology, as well as novel drug or vaccine candidates. This is 
illustrated here through studies on PEMs as synthetic vaccine candidates targeting the 
malaria parasite and the human immunodeficiency virus type-1 (HIV-1). In addition, 
various folded PEMs with ß-hairpin structures have been designed that target protein-
protein and protein-nucleic acid interactions, as well as others that interact with 
cellular receptors such as CXCR4 and the bacterial outer membrane protein LptD. In 
this last example, the PEMs possess a novel antibiotic activity that has so far not been 





Mimicry of the three-dimensional (3D) surface features of proteins important for 
function in smaller synthetic molecules - called Protein Epitope Mimetics (PEMs) - 
has grown in importance in recent years. This area of chemical biology is being 
driven forward rapidly by progress in genomics and proteomics, as well as by the 
massive growth in the 3D structural protein database (PDB). Efforts to design and 
synthesize PEMs frequently leads to novel organic molecules, peptidomimetics and 
foldamers, not found in natural products or traditional small drug-like molecules. This 
opens the prospect of uncovering new biologically active molecules that might be 
useful tools in efforts to understand biological molecular recognition, in the 
development of novel biomolecular probes, as well as novel drug or vaccine 
candidates. 
 Knowing at a structural level how proteins interact with other macromolecules 
provides an ideal starting point for PEM design. For example, protein-protein 
interactions (PPIs) and protein-nucleic acid interactions (PNIs) are often mediated by 
elements of secondary structure on the protein surface. Synthetic molecules that 
mimic these folded structures may then be useful inhibitors of protein-protein and 
protein-nucleic acid interactions. In addition, knowing at a structural level how 
antibodies recognize epitopes on pathogen-derived protective antigens opens new 
possibilities for applying PEMs in synthetic vaccine design, in the emerging field of 
structural vaccinology.[1] 
 Considerable scientific challenges remain, however, in transforming 3D 
structural information from the PDB into rationally designed PEMs with appropriate 
chemical and biological properties. Mutagenesis experiments can reveal energetically 
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important hot spots at protein-protein interfaces.[2] However, the internal dynamics of 
proteins, which can lead to structural changes over diverse time-scales, are more 
difficult to access experimentally, and yet exert a powerful influence upon binding 
affinity, and in ways that are difficult to predict from a single ground state crystal 
structure.[3] Notwithstanding these mechanistic problems, important progress in PEM 
design has been made by focusing on protein hot-spots and in optimizing surface 
complementarity upon binding to a macromolecular target. 
 
2. Design of ß-hairpin mimetics 
ß-Hairpin surface loops are found in many proteins, where they frequently mediate 
protein-protein and protein-nucleic acid interactions. A ß-hairpin loop is composed of 
two consecutive hydrogen-bonded antiparallel ß-strands connected by a turn segment 
(Figure 1). Many subtle variations can occur in backbone conformation within ß-
hairpin loops in folded proteins, depending upon the loop length and hydrogen-
bonding pattern between the two antiparallel ß-strands.[4] This structural diversity can 
be captured in ß-hairpin mimetics designed by transplanting the hairpin loop from a 
folded protein of known structure onto a semi-rigid hairpin-stabilizing template.[5] 
This affords a macrocyclic, conformationally constrained, template-bound ß-hairpin 
mimetic. One very convenient template is the dipeptide D-Pro-L-Pro, which 
(importantly) adopts a very stable type-II' ß-turn,[6] ideal for nucleating the preferred 
right-handed twist typically observed between adjacent antiparallel ß-strands in 
proteins. This approach was demonstrated through the design of mimetics of a hairpin 
loop in the receptor for IFNγ and CDR loops from IgG antibodies, as illustrated in 
Figure-1.[7] When transplanting a ß-hairpin loop from a known protein structure onto 
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this template, the N- and C-terminal loop residues adjacent to the template will be 
forced into a cross-strand hydrogen bonding geometry (Figure-1). The template then 
functions both to stabilize hairpin conformations and to fix the cross-strand hydrogen-
bonding register in the loop. 
An efficient method of synthesizing such ß-hairpin mimetics has been 
established.[8] Typically, a linear precursor is assembled by solid phase peptide 
chemistry, and then cyclized in solution and deprotected. This process is robust and 
amenable to parallel synthesis, allowing the production of small libraries of 
structurally related hairpin mimetics. Proteinogenic and non-proteinogenic amino 
acids, as well as an array of related building blocks can be used for synthesis, as a 
means to tailor and optimize structure and biological properties. This process forms 
the basis of the PEM-technology, which has been commercialized by Polyphor AG 
and applied to challenging pharmaceutical targets such as protein-protein interaction 
inhibitors that have proven difficult to address using traditional small drug-like 
molecules.[9] 
Over recent years, ß-hairpin mimetics have been investigated that bind with 
high affinity and specificity to many interesting biological targets. This includes 
molecules that bind to the Fc fragment of IgGs,[10] mimetics that bind to and inhibit 
serine proteases such as trypsin,[11] and mimetics that bind to RNA targets such as the 
TAR and RRE RNA from HIV-1.[12] Folded RNA segments represent particularly 
interesting targets for ß-hairpin mimetics. Recently, ß-hairpin mimics of the Tat 
protein were discovered that are pM inhibitors of the Tat-TAR interaction and 
discriminate between even closely related RNAs.[13] Interestingly, the structure of 
TAR RNA bound to one mimetic has a quite different conformation to that seen in the 
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RNA with no bound ligand, or bound to argininamide.[12e, 14] The complex internal 
dynamics of the TAR RNA seems to be particularly important in adapting and 
binding to the ß-hairpin shaped peptidomimetics. One mimetic has been shown to 
inhibit HIV-1 infection in whole cells. The mimetic is a nanomolar inhibitor of 
cellular HIV-1 replication, inhibiting replication in primary lymphocytes of a wide 
range of viral strains representing all the major HIV clades.[12f] 
A less obvious application of ß-hairpins is in mimicry of α-helical epitopes. In 
several cases, however, it was shown how the well-defined geometry of a hairpin 
scaffold can be exploited to display amino acid side chains so that they mimic the 
positions they adopt when attached at i and i+3/4 positions along a helical scaffold 
(Figure 2).[12h, 15] For example, a family of ß-hairpin mimetics was developed that 
mimic an α-helical epitope in the p53 protein and bind with nanomolar affinity to its 
interaction partner, the HDM2 protein.[15a, 15b, 16] 
Other applications include hairpin mimetics that target cell surface receptors, 
such as the chemokine receptor CXCR4 on lymphocytes,[17] and the outer membrane 
translocon LptD in Gram-negative bacteria (see below).[18] PEMs targeting CXCR4 
are very potent and selective inhibitors of this G-protein coupled receptor (GPCR), 
which in humans promotes chemotaxis in leukocytes, progenitor cell migration, and 
embryonic development of the cardiovascular, hematopoietic and central nervous 
systems. CXCR4 has also been associated with multiple types of cancers, where its 
overexpression/activation promotes metastasis, angiogenesis and tumor 
growth/survival. CXCR4 is also one of the co-receptors used by HIV-1 to gain entry 
to lymphocytes.[19] Molecules that antagonize CXCR4 are therefore potentially useful 
to induce mobilization of hematopoietic stem cells from the bone marrow to the 
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periphery, for example, for stem cell transplantation, as well as for anti-cancer and 
anti-HIV activity. A recent crystal structure illustrates in atomic detail how one ß-
hairpin peptide interacts with CXCR4.[20] 
 
3.  Synthetic vaccine design 
Conformationally constrained PEMs are also likely to find important 
applications in synthetic vaccine design.[21] Of special interest are epitopes on the 
surface of invading microorganisms that are recognized by antibodies that protect 
against infection - so-called protective or neutralizing antibodies. There is a rapidly 
growing number of crystal structures in the PDB of neutralizing antibody Fab 
fragments bound to their cognate pathogen-derived antigens.[22] Such crystal structures 
reveal the folded epitope against which a protective humoral immune response was 
elicited. One challenge is to design synthetic molecules that mimic these folded 
structures and that can be used to elicit a protective immune response against the 
pathogen.[23] A further challenge is to find a suitable method to deliver the epitope 
mimetics to the immune system, so that a strong specific (and protective) immune 
response is elicited in a diverse human population. Here the engineering of 
nanoparticles holds great promise for the development of new immunomodulatory 
agents.[24] Two examples from recent work illustrate how these challenges might be 
addressed. 
Our efforts to design a synthetic malaria vaccine focused initially upon the so-
called circumsporozoite (CS) protein, an immunodominant protective antigen on the 
surface of the sporozoite stage of Plasmodium falciparum, carried by live 
mosquitoes.[25] The central region of this membrane-anchored CS protein contains a 
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(NPNA)≈37 repeat region, which is highly immunogenic. Early attempts to exploit this 
repeat region in a clinical trial using a linear (NANP)3 peptide conjugated to tetanus 
toxin in alum,[26] gave disappointing results. In our approach, sequential rounds of 
epitope design, synthesis and testing were followed, to identify vaccine candidates 
that elicit primarily or exclusively antibodies that contribute to protection against 
sporozoite invasion of liver cells.  
The NPNA repeat has long been known to favor ß-turn conformations in 
solution[27] Indeed, a crystal structure of the peptide Ac-ANPNA-NH2 revealed the 
NPNA motif in a type-I ß-turn conformation (Figure 3).[28] However, it is still unclear 
how such ß-turns might propagate in the CS protein, containing multiple tandemly 
linked copies of the NPNA motif. It proved possible to stabilize ß-turn conformations 
in linear NPNA-repeats by substituting Pro for α-methyl-proline.[29] Further rounds of 
optimization, however, including studies of template-linked macrocyclic peptides,[30] 
led to a constrained derivative called UK40 (Figure 3), which proved to have 
structural and antigenic similarity to the repeat region of the native CS protein.[31] For 
delivery, this mimetic was coupled to a phospholipid (to give UK39) and incorporated 
into reconstituted influenza virus-like particles (also called virosomes, or 
immunopotentiating reconstituted influenza virosomes (IRIVs)).[30i, 31] IRIVs are 
spherical, unilamellar enveloped virus-like particles, prepared by detergent removal 
from a mixture of natural and synthetic phospholipid and influenza surface 
glycoproteins. Upon reconstitution from lipids, influenza proteins, and the lipo-
peptide antigen, the CS epitope mimetic should be displayed on the surface of the 
IRIV nanoparticles where it can be recognized by B cells. In this way, delivery of 
UK39 to mice and rabbits elicited high titres of sporozoite cross-reactive antibodies 
that inhibit invasion of hepatocytes by P. falciparum sporozoites.[31] 
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This approach was predicated upon the idea that several synthetic antigens, 
mimicking epitopes on different stages of the P. falicparum life cycle, might be 
combined to form a multicomponent, multi-stage vaccine. As a next step, a second 
lipopeptide was developed to elicit antibodies against the apical membrane antigen 1 
(AMA-1), a membrane protein that is located within the apical complex of the 
merozoite surface of the liver-stage parasite, and which is essential for invasion of 
erythrocytes.[32] A cyclized synthetic peptide (called AMA49-C1 as a phospholipid 
conjugate), based upon the semi-conserved loop I of domain III, was identified and 
shown to induce asexual blood-stage parasite growth inhibitory antibodies using the 
IRIV delivery system.[32a] Additional mimetics were also prepared and tested based on 
epitopes in the merozoite proteins MSP-1, MSP-3 and serine-repeat antigen 5.[33] 
In several phase I/II clinical studies conducted by Pevion AG in collaboration 
with the Swiss Tropical and Public Health Institute, the virosomally formulated UK-
39 and AMA49-C1 vaccine, was found to be well tolerated, and both components 
elicited strong specific antibody responses in all immunized volunteers.[34] A 
promising observation made during clinical trials in Africa was that the incidence of 
clinical malaria episodes in children receiving the vaccine was half the rate of the 
control children.[34d] These encouraging results suggest that further development of 
this approach to a multivalent malaria peptide vaccine may be worthwhile. 
In a second example, a different nanoparticle delivery vehicle is exemplified, 
made from components totally of synthetic origin. The Synthetic Virus-Like Particle 
(SVLP) delivery system exploits the unique chemical and physical properties of 
designed synthetic lipopeptide building blocks, which in aqueous buffers 
spontaneously self-assemble into homogeneous nanoparticles in the 20-30 nm size 
range.[35] The lipopeptide building blocks contain a parallel trimeric coiled-coil motif, 
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fused to a CD4+ T-helper epitope (Figure-4). The lipid portion can be a bacterial TLR 
ligand such as Pam2Cys or Pam3Cys, which is coupled to one terminus of the peptide 
chain. A synthetic PEM can be coupled to the other end of the peptide chain. Self-
assembly into SVLPs occurs spontaneously upon dissolving in aqueous buffer, driven 
by formation of trimeric coiled-coil helical bundles and then by association of 
multiple bundles into a micelle like particle with the lipid chains buried in the core of 
the nanoparticle. SVLPs present an array of about 70-80 copies of the epitope 
mimetic over the surface of the nanoparticle.[35a-c] Dendritic cells bind rapidly to 
SVLPs, which are internalized using multiple endocytic routes, dominated by 
caveolin-independent lipid raft-mediated macropinocytosis.[35e] Processing then occurs 
more slowly by proteolytic cleavage of the lipopeptides. The processing is highly 
effective, however, as evidenced by strong epitope-specific immune responses 
induced in animals, without need for external adjuvants. One application of the SVLP 
technology is described below, focusing on the V3 loop in the HIV-1 envelope 
glycoprotein gp120. 
The ß-hairpin V3 loop is a highly immunogenic region of the HIV-1 envelope 
glycoprotein gp120 that becomes exposed on the viral surface after binding to the 
primary receptor CD4 on target cells binds.[36] Several crystal structures are now 
available of Fab fragments from neutralizing antibodies bound to peptides derived 
from the V3 loop, including one of the mAb F425-B4e8.[37] The linear V3 peptide is 
flexible in free solution, but a constrained V3 loop mimetic was prepared[37] by 
transplanting the loop sequence onto the D-Pro-L-Pro template.[35d, 38] 1H-NMR studies 
revealed a very close structural similarity between this mimetic and the V3 peptide 
bound to the F425-B4e8 antibody.[35d] 
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 To study immune responses, the V3 loop mimetic was linked to SVLPs 
through a unique Cys residue near the C-terminus of the SVLP lipopeptide building 
blocks. A computer model of the resulting SVLPs (Figure 4), based on extensive 
biophysical data, illustrates the dense array of epitope mimetics displayed on the 
surface of the nanoparticle. These V3-SVLPs proved to be highly immunogenic in 
rabbits, eliciting high titers of V3-mimetic specific IgG antibodies, including 
antibodies that bind specifically to recombinant gp120 by ELISA. Moreover, some of 
the antibodies generated showed HIV-1 neutralizing activity in whole cell infection 
assays.[35d]  
 These results illustrate a chemistry-based and structure-driven approach to 
vaccine discovery, which may allow the design of many new vaccine candidates 
targeting both infectious and chronic human diseases. The SVLP technology and its 
use in synthetic vaccine design is now being pursued by the company Virometix AG. 
 
4. Discovery of the ß-hairpin antibiotics 
 ß-Hairpin-shaped peptides are found within the large family of naturally 
occurring cationic antimicrobial peptides (CAPs), which play important roles in 
innate immunity in many different organisms, by providing a first line of defense in 
the host against viral and bacterial infection.[39] Many CAPs show broad-spectrum 
antimicrobial activity in the micromolar range, typically by causing lysis of microbial 
cell membranes.[39b] This lytic action, however, can also occur with human cells (e.g. 
red blood cells), albeit at higher concentrations. We set out to investigate whether 
structurally related ß-hairpin PEMs could be developed that retain good antimicrobial 
activity, but with a reduced lytic (toxic) effects on human red blood cells. 
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 One group of CAPs, including the protegrins, polyphemusins, tachyplesin, 
arenicin and Θ-defensin, possess ß-hairpin structures stabilized by disulfide 
bridges.[39] Macrocyclic peptidomimetics of these CAPs could be designed using a D-
Pro-L-Pro template to stabilize folded ß-hairpin structures. In this way, peptides were 
discovered that indeed possess broad-spectrum antimicrobial activity in the low 
micromolar range, comparable to that seen with protegrin I, but with much reduced 
lytic activity against human red blood cells.[40] Attempts to improve further the 
antimicrobial activity, by an iterative process of library synthesis and screening, led to 
the discovery of cyclic peptidomimetics with a novel type of antimicrobial activity.[18a] 
This is illustrated by the cyclic peptide L27-11 (Figure 5), which shows antimicrobial 
activity in the nanomolar range specifically against Gram-negative Pseudomonas sp. 
Moreover, the enantiomeric form is essentially inactive (MIC ≥ 32 µg/ml), suggesting 
a highly enantioselective interaction with a chiral target, rather than a non-
stereoselective interaction with lipid chains of the cell membrane, which is typical of 
many CAPs. NMR studies showed that L27-11 indeed adopts ß-hairpin conformations 
in solution, and that the ß-hairpin structure is important for antimicrobial activity.[41] 
 The mechanism of action of these novel antibiotics is of great interest. L27-11 
does not cause lysis of cell membranes. The target of the antibiotic was revealed by 
two complementary approaches, namely, photoaffinity labeling experiments and a 
forward genetic screen for resistance determinants in P. aeruginosa. Both approaches 
identified the same ß-barrel outer membrane (OM) protein, LptD, as the likely target. 
Over the past 10 years much has been learnt about the function of LptD in E. coli and 
related Gram-negative bacteria.[42] LptD is present in the OM of most Gram-negative 
bacteria in a complex with the lipoprotein LptE.[43] The LptD/E complex has an 
essential function in the biogenesis of the outer cell membrane. 
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The inner membrane (IM) of Gram-negative bacteria is a lipid bilayer 
composed of phospholipids, whereas the OM is an asymmetric bilayer composed of 
phospholipids in the inner and lipopolysaccharide (LPS) in the outer leaflet (Figure 5). 
This asymmetric OM does not form spontaneously, but rather requires dedicated 
machinery for assembly during cell growth. New LPS molecules are assembled in the 
cytoplasm and at the IM, are then extracted from the IM, transported across the 
periplasm, and then translocated from the periplasmic side to the outer surface of the 
OM. Seven essential Lpt (lipopolysaccharide transport) proteins (LptA-G) are known 
to mediate this transport process.[42b, 44] The LptD/E complex has the important 
function of translocating LPS from the periplasm into the outer leaflet of the OM. 
Upon exposure to L27-11, defects in OM structure can be seen by transmission 
electron microscopy within P. aeruginosa cells.[18a] This and other experimental 
evidence support the hypothesis that the antibiotic, by interaction with LptD, inhibits 
LPS transport to the cell surface, leading to disruption of OM biogenesis.[18b] So far no 
other small molecules or natural products are known that target the essential LptD/E 
translocon in the OM of Gram-negative bacteria. 
Given the potency of the antibiotic against P. aeruginosa, and its novel 
mechanism of action, efforts have been made to develop a lead for clinical 
development. P. aeruginosa is one of the seven so-called ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter spp.), a 
selection of antibiotic-resistant bacteria highlighted by the Infectious Diseases Society 
of America (IDSA) that increasingly cause difficult-to-treat infections in hospitals and 
the wider community.[45] The company Polyphor AG has now developed related 
PEMs such as POL7001, which has the same potent antimicrobial activity, but much-
 14 
improved stability in human plasma.[18a] In addition, a clinical candidate called 
POL7080 with optimized ADMET properties has been identified, which has recently 
completed successfully a human phase I clinical study.[46] In future work, it will be 
fascinating to see whether related ß-hairpin antibiotics can be found that target other 
essential ß-barrel OM proteins, such as LptD in the other Gram-negative bacteria 
highlighted by the ISDA. 
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Figure 1. Conformationally constrained ß-hairpin mimetics can be designed by 
transplanting the hairpin sequence from the protein of interest onto a suitable hairpin-




Figure 2. Using a ß-hairpin to mimic an α-helix. In this case, the helical epitope seen 
(right) in the crystal structure of a p53-derived peptide bound to a domain of HDM2 
(PDB 1YCR),[47] is converted into a ß-hairpin PEM that binds to HDM2 (left) with 




Figure 3. A malaria vaccine based upon a constrained peptide from the NPNA 
repeats in the CS protein. A, Crystal structure of Ac-ANPNA-NH2.[28] B, The 
mimetics UK39 and UK40. C, Average NMR solution structure of the mimetic 
UK40.[31] D, Cartoon representing the display of an epitope mimetic on the surface of 




Figure 4. Design of an HIV-1 V3 loop mimetic. A, Crystal structure of a V3-derived 
linear peptide (cyan) bound to the Fab fragment of mAb F425-B4e8 (gray/yellow 
surface) (PDB 2QSC).[37] The solution structure of a V3 loop mimetic (purple, with D-
Pro-L-Pro template (orange) at the top) is shown superimposed on the bound linear 
peptide.[35d] B, Conjugation of the V3 loop mimetic (boxed) with a lipopeptide 
building block. This lipopeptide assembles spontaneously into SVLPs in aqueous 
buffer. C, A computer model is shown of an SVLP particle with multiple V3 epitope 




Figure 5. A, The ß-hairpin antibiotic L27-11 that interacts with LptD. B, NMR 
solution structure of L27-11.[41] C, The double membrane of Gram-negative bacteria. 
LptD is an OM protein that is required for translocation of LPS molecules from the 
periplasm to the cell surface during cell wall biogenesis (see text). 
 
 
 
 
 
 
 
 
 
 
